Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial

Ladetto, Marco; Cortelazzo, Sergio; Ferrero, Simone; Evangelista, Andrea; Mian, Michael; Tavarozzi, Rita; Zanni, Manuela; Cavallo, Federica; Rocco, Alice Di; Stefoni, Vittorio; Pagani, Chiara; Re, Alessandro; Chiappella, Annalisa; Balzarotti, Monica; Zilioli, Vittorio Ruggero; Silva, Maria Gomes da; Arcaini, Luca; Molinari, Anna Lia; Ballerini, Filippo; Ferreri, Andrés J.M.; Puccini, Benedetta; Benedetti, Fabio; Stefani, Piero Maria; Narni, Franco; Casaroli, Ivana; Stelitano, Caterina; Ciccone, Giovannino; Vitolo, Umberto; Martelli, Maurizio

doi:10.1016/s2352-3026(20)30358-6

Cited by 34 publications

(32 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this view, it is of relevance the recent report of a prospective trial by the FIL cooperative study group indicating that Lenalidomide maintenance after an induction with a RHDS-like scheme and ASCT consolidation prolongs PFS in MCL patients. [12] In summary, the data here presented could serve as a solid benchmark for newer approaches. Indeed, the results indicated that adults with MCL may have a long life expectancy, with a high proportion of patients surviving long-term with no evidence of disease.…”

Section: S-3 D)mentioning

confidence: 86%

See 1 more Smart Citation

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term

Cortelazzo

Mian

Evangelista

et al. 2021

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Section: S-3 D)mentioning

confidence: 86%

Section: To the Editormentioning

confidence: 99%

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term

Cortelazzo

Mian

Evangelista

et al. 2021

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

“…Combined with IFN-DC-based vaccination, the immunomodulatory drug, lenalidomide, which was approved for R/R FL patients [ 2 ] and active for untreated FL [ 174 ] and MCL patients [ 28 , 175 ], increased the frequency of IFN-γ production by NK cells in response to Karpas-422, a DLBCL cell line harboring t(14,18) translocation [ 176 ]. Lenalidomide reduced IL-10 released from T cells and significantly reduced Treg frequency.…”

Section: Vaccination With Immunogenic Cell Death Tumorsmentioning

confidence: 99%

Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment

Watanabe

2021

Cancers

View full text Add to dashboard Cite

A dominant paradigm being developed in immunotherapy for hematologic malignancies is of adaptive immunotherapy that involves chimeric antigen receptor (CAR) T cells and bispecific T-cell engagers. CAR T-cell therapy has yielded results that surpass those of the existing salvage immunochemotherapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after first-line immunochemotherapy, while offering a therapeutic option for patients with follicular lymphoma (FL) and mantle cell lymphoma (MCL). However, the role of the innate immune system has been shown to prolong CAR T-cell persistence. Cluster of differentiation (CD) 47-blocking antibodies, which are a promising therapeutic armamentarium for DLBCL, are novel innate immune checkpoint inhibitors that allow macrophages to phagocytose tumor cells. Intratumoral Toll-like receptor 9 agonist CpG oligodeoxynucleotide plays a pivotal role in FL, and vaccination may be required in MCL. Additionally, local stimulator of interferon gene agonists, which induce a systemic anti-lymphoma CD8+ T-cell response, and the costimulatory molecule 4-1BB/CD137 or OX40/CD134 agonistic antibodies represent attractive agents for dendritic cell activations, which subsequently, facilitates initiation of productive T-cell priming and NK cells. This review describes the exploitation of approaches that trigger innate immune activation for adaptive immune cells to operate maximally in the tumor microenvironment of these lymphomas.

show abstract

“…For patients with DLBCL who achieved CR or PR by R-CHOP induction, a randomized phase III trial demonstrated that Len maintenance monotherapy in elderly patients with DLBCL is safe and effective (mPFS was not reached, vs. 58.9 months with placebo; HR, 0.708; 95% CI, 0.537–0.933; p = 0.01) ( Thieblemont et al, 2017 ). Despite inescapable toxicity (63%, vs. 12% in observation group; p < 0·0001), Len improved PFS in patients with an MCL post-autograft (NCT02354313) ( Ladetto et al, 2021 ).…”

Section: Clinical Applicationsmentioning

confidence: 99%

Ikaros Proteins in Tumor: Current Perspectives and New Developments

Xia

Yuan

Han

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Ikaros is a zinc finger transcription factor (TF) of the Krüppel family member, which significantly regulates normal lymphopoiesis and tumorigenesis. Ikaros can directly initiate or suppress tumor suppressors or oncogenes, consequently regulating the survival and proliferation of cancer cells. Over recent decades, a series of studies have been devoted to exploring and clarifying the relationship between Ikaros and associated tumors. Therapeutic strategies targeting Ikaros have shown promising therapeutic effects in both pre-clinical and clinical trials. Nevertheless, the increasingly prominent problem of drug resistance targeted to Ikaros and its analog is gradually appearing in our field of vision. This article reviews the role of Ikaros in tumorigenesis, the mechanism of drug resistance, the progress of targeting Ikaros in both pre-clinical and clinical trials, and the potential use of associated therapy in cancer therapy.

show abstract

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial

Cited by 34 publications

References 24 publications

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term

Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment

Ikaros Proteins in Tumor: Current Perspectives and New Developments

Contact Info

Product

Resources

About